AKT1 and diabetic retinopathy: Specific formulations and bioactive compounds regulate pathways including PI3K/Akt, Nrf2/HO-1, and VEGF, contributing to better glycemic control and reduced complications such as diabetic retinopathy, cardiomyopathy, osteoporosis, and peripheral neuropathy.